Tirzepatide emerges a groundbreaking treatment agent for individuals facing type 2 diabetes. As a dual receptor activator, it targets both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic https://jeanmktx881911.p2blogs.com/39014095/tirzepatide-a-novel-glp-1-and-gip-receptor-agonist